Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Valeant Pharma (VRX) Pushes to Session Highs
August 9, 2016 2:26 PM EDTValeant Pharma (NYSE: VRX) continues to push to the highs of the session following results and better-than-expected guidance. Shares are up 23.5% on volume that is running 5x the norm. Short covering is seen as a contributor to today's upside.
... MoreValeant (VRX) Provides Plenty to Support Bullish Thesis - Guggenheim
August 9, 2016 10:25 AM EDTGuggenheim analyst Louise Chen reiterated a Buy rating and $55 price target on Valeant Pharmaceuticals (NYSE: VRX) following a Q2 miss but reaffirmed '16 EPS guidance.
Chen notes, "VRX has noted since its 1Q16 call that it expects the business to recover in 2H16 as it moves past the issues with its derm business, and achieved its objective to report a 40%/60% earnings split between 1H16/2H16. Therefore, our investment thesis remains intact, and we continue to believe that VRX's growth... More
Valeant Pharma (VRX) Misses Q2 EPS by 8c, Reaffirms Guidance; Will Divest Ruconest Rights in N.A.
August 9, 2016 6:01 AM EDTValeant Pharma (NYSE: VRX) reported Q2 EPS of $1.40, $0.08 worse than the analyst estimate of $1.48. Revenue for the quarter came in at $2.42 billion versus the consensus estimate of $2.46 billion.
Valeant Pharma reaffirmed FY2016 guidance. Adjusted EBITDA (non-GAAP) is expected to be in the range of $4.80 - $4.95 billion, in-line with consensus, although many expected the company to lower EBITDA guidance.
"We continue to make progress towards stabilizing the organization," said Joseph C. Papa, chairman and... More
